Levothyroxine sodium - IBSA

Drug Profile

Levothyroxine sodium - IBSA

Alternative Names: L-thyronine-sodium - IBSA; L-thyroxine-sodium - IBSA; Levothyroxine - IBSA; Levothyroxine sodium liquid gel capsules - IBSA; Levothyroxine sodium oral solution; Levothyroxine-sodium-I-125 - IBSA; LT4 - IBSA; Monosodium-L-thyroxine-hydrate - IBSA; T4 - IBSA; Thyroxine-I-125 - IBSA; Thyroxine-sodium - IBSA; Tirosint; Tirosint - IBSA; Tirosint-SOL

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator IBSA
  • Developer Akrimax Pharmaceuticals; IBSA
  • Class Aromatic amino acids; Small molecules; Thyroid hormones
  • Mechanism of Action Thyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypothyroidism

Most Recent Events

  • 15 Dec 2016 Registered for Hypothyroidism in USA (PO) (3227235; 9211568)
  • 30 May 2015 IBSA completes a phase II trial in Hypothyroidism (In volunteers) in Switzerland (ISRCTN12149022)
  • 21 Jan 2015 Phase II trials in Hypothyroidism (In volunteers) in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top